8-K: Eledon Pharmaceuticals Reports Positive Data and Financial Results for 2024, Cash Runway Extended to End of 2026

Eledon Pharmaceuticals announces positive clinical data, financial results for 2024, and an extended cash runway through 2026, driven by a successful $85 million offering.

Summary

• Eledon Pharmaceuticals reported its fourth quarter and full year 2024 operating and financial results.
• Tegoprubart was used in a second transplant of a genetically modified pig kidney into a human at Massachusetts General Hospital.
• Positive initial data was reported from the first three subjects with type 1 diabetes treated with tegoprubart following islet transplantation at UChicago Medicine.
• Topline results from the Phase 2 BESTOW trial of tegoprubart in kidney transplantation are expected in the fourth quarter of 2025.
• An oversubscribed $85 million underwritten offering extends the company's cash runway to the end of 2026.
• Cash, cash equivalents, and short-term investments totaled $140.2 million as of December 31, 2024, compared to $78.2 million at September 30, 2024.
• Research and development expenses for the fourth quarter of 2024 were $17.9 million, compared to $7.1 million for the same period in 2023.
• General and administrative expenses for the fourth quarter of 2024 were $6.8 million, compared to $3.3 million for the comparable period in 2023.
• Net loss for the fourth quarter of 2024 was $44.6 million, or $0.64 per basic share, compared with a net loss of $30.1 million, or $1.00 per basic share, for the comparable period in 2023.
• Research and development expenses for the year ended December 31, 2024, were $52.0 million, compared to $30.3 million for the comparable period in 2023.
• General and administrative expenses for the year ended December 31, 2024, were $18.6 million, compared to $12.7 million for the comparable period in 2023.
• Net loss for the year ended December 31, 2024, was $36.2 million, or $0.75 per basic share, compared with a net loss of $116.5 million, or $4.73 per basic share, in 2023.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and a strengthened financial position, increased expenses and net losses temper the overall outlook.

Positives

• Tegoprubart shows promise in preventing organ rejection in both kidney and islet transplants.
• The company's financial position is strong, with sufficient cash to fund operations through the end of 2026.
• The successful capital raise indicates investor confidence in the company's prospects.
• Positive initial data from islet transplant trial suggests potential for insulin independence without tacrolimus.

Negatives

• The company experienced a net loss of $44.6 million for the fourth quarter of 2024.
• Research and development expenses increased significantly in 2024 compared to 2023.
• General and administrative expenses also increased in 2024 compared to 2023.

Risks

• The success of clinical trials is uncertain, and results may not be favorable.
• Interactions with regulators and clinical sites could impact clinical development timelines.
• The company's capital resources may not be sufficient to fund all planned clinical trials.
• The ongoing coronavirus pandemic could have an impact on the company's operations.

Future Outlook

The company anticipates reporting updated interim clinical data from the Phase 1b trial in Summer 2025 and topline results from the Phase 2 BESTOW trial in the fourth quarter of 2025, and expects current cash to fund operations to the end of 2026.

Management Comments

• Tegoprubart was a cornerstone immunosuppression component in recent historic procedures including kidney xenotransplant and islet transplants in patients with type 1 diabetes, said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon.
• The results from these landmark studies together with the encouraging allograft kidney transplant clinical data we have shared continue to reinforce tegoprubarts broad potential to protect transplanted organs and cells, regardless of the transplant type and the organ source.
• We are entering 2025 from a position of balance sheet strength and we are on track to deliver on multiple key milestones in the coming months, including topline results from our Phase 2 BESTOW trial in the fourth quarter of 2025.

Industry Context

Eledon's work in xenotransplantation and islet transplantation places them at the forefront of innovative approaches to address organ shortages and improve outcomes for patients with life-threatening conditions, aligning with broader industry trends in regenerative medicine and advanced therapies.

Comparison to Industry Standards

• The use of tegoprubart in xenotransplantation aligns with efforts by companies like United Therapeutics and eGenesis, which are also exploring xenotransplantation to address organ shortages.
• The islet transplantation program at UChicago Medicine is a leading center in this field, comparable to other institutions like the University of Alberta, which have pioneered islet transplantation protocols.
• Eledon's Phase 2 BESTOW trial is similar to other clinical trials evaluating novel immunosuppressants in kidney transplantation, such as those conducted by companies like Novartis and Roche with their respective therapies.

Stakeholder Impact

• Shareholders benefit from the extended cash runway and potential for future growth.
• Employees benefit from increased headcount and compensation.
• Patients with life-threatening conditions may benefit from the development of new immune-modulating therapies.
• The company's financial stability strengthens its relationships with suppliers and creditors.

Next Steps

• Report updated interim clinical data from the ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients in Summer 2025.
• Report topline results from the Phase 2 BESTOW trial of tegoprubart in kidney transplantation in 4Q 2025.
• Report updated interim clinical data from the investigator-led clinical trial with UChicago Medicine for pancreatic islet transplantation in subjects with type 1 diabetes in 2025.

Key Dates

Keywords

tegoprubart, kidney transplantation, islet transplantation, immunosuppression, clinical trials, Eledon Pharmaceuticals, financial results, organ rejection, xenotransplant, BESTOW trial